Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Rating of “Hold” by Analysts

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have been given a consensus recommendation of “Hold” by the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $17.50.

Several analysts have recently commented on the company. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Wall Street Zen cut Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Cantor Fitzgerald assumed coverage on Entrada Therapeutics in a report on Wednesday, April 1st. They set an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, CFO Kory James Wentworth sold 2,500 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $12.95, for a total transaction of $32,375.00. Following the sale, the chief financial officer owned 119,010 shares in the company, valued at approximately $1,541,179.50. This represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Natarajan Sethuraman sold 25,907 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.39, for a total value of $398,708.73. Following the transaction, the insider directly owned 216,317 shares in the company, valued at $3,329,118.63. This trade represents a 10.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 43,407 shares of company stock worth $661,034 over the last ninety days. Company insiders own 9.49% of the company’s stock.

Hedge Funds Weigh In On Entrada Therapeutics

Several large investors have recently made changes to their positions in TRDA. Russell Investments Group Ltd. lifted its stake in shares of Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after acquiring an additional 3,707 shares during the period. State of Wyoming lifted its stake in shares of Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after acquiring an additional 4,295 shares during the period. AXQ Capital LP acquired a new position in shares of Entrada Therapeutics during the third quarter valued at $67,000. Occudo Quantitative Strategies LP acquired a new position in shares of Entrada Therapeutics during the second quarter valued at $68,000. Finally, Jain Global LLC acquired a new position in shares of Entrada Therapeutics during the third quarter valued at $69,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

Shares of NASDAQ:TRDA opened at $6.46 on Monday. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $16.45. The company’s fifty day moving average is $9.83 and its 200-day moving average is $10.71. The company has a market capitalization of $250.78 million, a PE ratio of -1.62 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.11. The company had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%. On average, analysts forecast that Entrada Therapeutics will post -4.12 EPS for the current year.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.